Microsoft Corp MSFT:NASDAQ

Last Price$213.67NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/10/20

Today's Change0(0.00%)
Bid (Size)$214.25 (1)
Ask (Size)$214.26 (1)
Day Low / HighN/A - N/A
Volume26.2 M

FDA Extends Review of Novartis' Multiple Sclerosis Therapeutic Ofatumumab

5:39AM ET 6/03/2020 MT Newswires
Novartis AG (NVS) said that the US Food and Drug Administration has extended its review of the company's supplemental biologics license application for the B-cell therapy ofatumumab for patients with relapsing multiple sclerosis.

The pharmaceutical firm did not specify the reason behind the extended review but said it expects the agency to issue its opinion in September.

Novartis also said that it still anticipates regulatory approval of the drug in Europe in Q2 of 2021.

Price: 85.50, Change: -0.96, Percent Change: -1.11